II
CTMX icon

Inspire Investing’s CytomX Therapeutics CTMX Stock Holding History

Inspire Investing’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$30 Sell
6
-2
-25% -$10 ﹤0.01% 1086
2025
Q4 		$32 Sell
8
-522,474
-100% -$1.98M ﹤0.01% 1086
2025
Q3 		$1.67M Buy
+522,482
New +$1.18M 0.16% 145
2020
Q2 		– Sell
-53
Closed – – 550
2020
Q1 		$0 Buy
+53
New +$370 ﹤0.01% 753
2018
Q1 		– Sell
-58
Closed -$1K – 312
2017
Q4 		$1K Buy
+58
New +$1.2K ﹤0.01% 853

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Inspire Investing's CTMX Position: Q1 2026 in Review

Inspire Investing reduced its CytomX Therapeutics (CTMX) stake by 25% in Q1 2026, selling an estimated $10 and leaving 6 shares worth $30. The position accounts for ﹤0.01% of the portfolio, ranked #1086.

Inspire Investing first reported a position in CTMX in Q4 2017 and has held it in 5 quarters since. The position peaked at $1.67M in Q3 2025. 179 funds tracked by Wall St. Rank hold CTMX as of Q1 2026.

  • Inspire Investing held 6 shares of CytomX Therapeutics worth $30 as of Q1 2026.
  • Inspire Investing sold 2 CytomX Therapeutics shares in Q1 2026, an estimated $10.
  • CytomX Therapeutics made up ﹤0.01% of Inspire Investing's portfolio in Q1 2026, its #1086 holding.
  • Inspire Investing first reported a position in CytomX Therapeutics in Q4 2017 and has held it in 5 quarters since.
  • Inspire Investing's CytomX Therapeutics position peaked at $1.67M in Q3 2025.
  • 179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2026.

Based on Inspire Investing's 13F filing for Q1 2026, filed 23 Apr 2026.